Invited commentary on: YMSY-D-23-01181_R2. Overexpression of human DNA polymerase theta (POLQ) is a biomarker of aggressive and DNA repair-deficient papillary thyroid cancers.
作者信息
Kim Lawrence T
机构信息
Division of Surgical Oncology and Endocrine Surgery, Department of Surgery, University of North Carolina, Chapel Hill, NC.
出版信息
Surgery. 2024 Nov;176(5):1388-1389. doi: 10.1016/j.surg.2024.07.024. Epub 2024 Aug 20.
PMID:39168727
Abstract
摘要
相似文献
1
Invited commentary on: YMSY-D-23-01181_R2. Overexpression of human DNA polymerase theta (POLQ) is a biomarker of aggressive and DNA repair-deficient papillary thyroid cancers.
Surgery. 2024 Nov;176(5):1388-1389. doi: 10.1016/j.surg.2024.07.024. Epub 2024 Aug 20.
2
Overexpression of human DNA polymerase theta is a biomarker of aggressive and DNA repair-deficient papillary thyroid cancers.
Surgery. 2024 Nov;176(5):1380-1387. doi: 10.1016/j.surg.2024.05.006. Epub 2024 Jun 18.
3
Epidermal growth factor receptor overexpression is a marker for adverse pathologic features in papillary thyroid carcinoma.
J Surg Res. 2013 Nov;185(1):217-24. doi: 10.1016/j.jss.2013.05.003. Epub 2013 May 23.
4
Expression of WD Repeat Domain 5 (WDR5) is Associated with Progression and Reduced Prognosis in Papillary Thyroid Carcinoma.
Med Sci Monit. 2019 May 20;25:3762-3770. doi: 10.12659/MSM.915847.
5
[Histopatological and molecular genetic characteristics of clinically aggressive variants of papillary thyroid carcinoma].
Arkh Patol. 2019;81(1):46-51. doi: 10.17116/patol20198101146.
6
Lymph node metastasis-dependent molecular classification in papillary thyroid carcinoma defines aggressive metastatic outgrowth.
Clin Transl Med. 2023 Mar;13(3):e1211. doi: 10.1002/ctm2.1211.
7
Quantitative assessment of RASSF1A methylation as a putative molecular marker in papillary thyroid carcinoma.
Surgery. 2013 Dec;154(6):1255-61; discussion 1261-2. doi: 10.1016/j.surg.2013.06.025.
8
[Expression of microRNA-221 and IL-17 in papillary thyroid carcinoma and correlation with clinicopathologic features].
Zhonghua Bing Li Xue Za Zhi. 2017 Mar 8;46(3):160-165. doi: 10.3760/cma.j.issn.0529-5807.2017.03.004.
9
Absence of BRAF V600E in non-infiltrative, non-invasive follicular variant of papillary thyroid carcinoma.
Histopathology. 2015 Oct;67(4):579-82. doi: 10.1111/his.12680. Epub 2015 Apr 9.
10
Evaluation of the expression levels of BRAF mRNA in primary tumors of thyroid cancer using an ultrasensitive mutation assay.
BMC Cancer. 2020 May 1;20(1):368. doi: 10.1186/s12885-020-06862-w.
Zotero 插件